procarbazine has been researched along with Disease Exacerbation in 79 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 9.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 9.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| " The relative safety of accelerated fractionated radiotherapy, as used in this study with carboplatin, enables concomitant full-dose administration of chemotherapy or radiosensitizing agents in glioblastoma multiforme patients." | 9.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 8.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 7.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| "To determine the efficacy of the combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas after failure of either previous radiotherapy alone or previous radiotherapy plus nitrosourea-based chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 6.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 6.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma." | 5.12 | PCV chemotherapy for recurrent glioblastoma. ( Dichgans, J; Dietz, K; Fischer, J; Herrlinger, U; Schmidt, F; Weller, M, 2006) |
| "Procarbazine hydrochloride (PCB) is one of the few anticancer drugs with activity against high-grade gliomas." | 5.12 | The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. ( Alavi, JB; Batchelor, TT; Carson, KA; Fisher, JD; Grossman, SA; Hammour, T; Lesser, G; Mikkelsen, T; Phuphanich, S; Supko, JG, 2006) |
| "The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas." | 5.10 | Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003) |
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 5.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 5.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| " The relative safety of accelerated fractionated radiotherapy, as used in this study with carboplatin, enables concomitant full-dose administration of chemotherapy or radiosensitizing agents in glioblastoma multiforme patients." | 5.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 4.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 3.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| "The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years." | 3.85 | Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. ( Bendavid, E; Chang, DT; Chin, AL; Durkee, BY; Harris, JP; Kim, H; Kumar, KA; Maruyama, S; Owens, DK; Pitt, A; Pollom, EL; Qian, Y; Soltys, SG, 2017) |
| "The proportion of intravenous drug abusers (IVDA) in HIV-HD (38%) is higher than in French HIV-infected population as a whole (20." | 3.78 | Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. ( Andrieu, JM; Brice, P; Colonna, P; Gastaut, JA; Lévy, R; Raphaël, M; Taillan, B; Tourani, JM, 1995) |
| "We collected 6 case-reports of symptomatric non removable low grade fibrillary astrocytoma of adults treated with a procarbazine-CCNU-vincristine chemotherapy regimen." | 3.72 | [Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults]. ( Alchaar, H; Bleuse, A; Bondiau, PY; Bourg, V; Brunetto, JL; Chanalet, S; Chatel, M; Courdi, A; Darcourt, J; Fauchon, F; Fontaine, D; Frénay, M; Grellier, P; Guibert, F; Lanteri-Minet, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Paquis, V; Ramaioli, A; Rasendrarijao, D; Vandenbos, F, 2004) |
| "The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy." | 3.71 | PCV chemotherapy for recurrent glioblastoma multiforme. ( Groeneveld, GJ; Heimans, JJ; Kappelle, AC; Postma, TJ; Sneeuw, KC; Taphoorn, MJ; van den Bent, MJ; van Groeningen, CJ; Zonnenberg, BA, 2001) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "To determine the efficacy of the combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas after failure of either previous radiotherapy alone or previous radiotherapy plus nitrosourea-based chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 2.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| "Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed." | 2.73 | Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. ( Bourg, V; Chanalet, S; Fauchon, F; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Paquis, P; Ramaioli, A; Vandenbos, F, 2007) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 2.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity." | 2.71 | Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004) |
| " Despite increased hematotoxicity, moderate dose escalation is safe for the majority of the patients with G-CSF assistance and standard supportive treatment." | 2.69 | Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). ( Diehl, V; Engel, C; Loeffler, M; Schmitz, S; Tesch, H, 2000) |
| "We document a high incidence of aseptic bone necrosis, possibly related to prednisolone." | 1.38 | Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. ( Aurlien, E; Blystad, AK; Fiskvik, IH; Fosså, A; Hole, KH; Holte, H; Ikonomou, IM; Kolstad, A; Lauritzsen, GF, 2012) |
| "The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications." | 1.34 | [Our experiences in treating patients with Hodgkin disease in the last decade]. ( Gergely, L; Illés, A; Keresztes, K; Miltényi, Z; Ress, Z; Simon, Z; Vadász, G; Váróczy, L, 2007) |
| "Treatment strategies in Hodgkin's disease have an impact on different risk factors." | 1.32 | Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. ( Dieckmann, K; Heinzl, H; Hofmann, J; Pötter, R; Schellong, G; Wagner, W, 2003) |
| "One hundred and fifty-six patients with multiple myeloma were treated over a period of 12 years at St." | 1.29 | Myeloma during a decade: clinical experience in a single centre. ( Carter, M; Clark, PI; Ganjoo, RK; Gregory, W; Johnson, PW; Lim, JM; Love, SB; Mahmoud, MM; Malpas, JS; Williams, AH, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (24.05) | 18.2507 |
| 2000's | 39 (49.37) | 29.6817 |
| 2010's | 20 (25.32) | 24.3611 |
| 2020's | 1 (1.27) | 2.80 |
| Authors | Studies |
|---|---|
| André, MPE | 1 |
| Carde, P | 2 |
| Viviani, S | 2 |
| Bellei, M | 1 |
| Fortpied, C | 1 |
| Hutchings, M | 1 |
| Gianni, AM | 2 |
| Brice, P | 3 |
| Casasnovas, O | 1 |
| Gobbi, PG | 1 |
| Zinzani, PL | 1 |
| Dupuis, J | 1 |
| Iannitto, E | 1 |
| Rambaldi, A | 1 |
| Brière, J | 1 |
| Clément-Filliatre, L | 1 |
| Heczko, M | 1 |
| Valagussa, P | 2 |
| Douxfils, J | 1 |
| Depaus, J | 1 |
| Federico, M | 1 |
| Mounier, N | 1 |
| Skoetz, N | 1 |
| Will, A | 1 |
| Monsef, I | 1 |
| Brillant, C | 1 |
| Engert, A | 8 |
| von Tresckow, B | 1 |
| Qian, Y | 1 |
| Maruyama, S | 1 |
| Kim, H | 1 |
| Pollom, EL | 1 |
| Kumar, KA | 1 |
| Chin, AL | 1 |
| Harris, JP | 1 |
| Chang, DT | 1 |
| Pitt, A | 1 |
| Bendavid, E | 1 |
| Owens, DK | 1 |
| Durkee, BY | 1 |
| Soltys, SG | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Fong, M | 1 |
| Boyle, S | 1 |
| Gutta, N | 1 |
| Cairncross, JG | 2 |
| Wang, M | 1 |
| Jenkins, RB | 2 |
| Shaw, EG | 1 |
| Giannini, C | 1 |
| Brachman, DG | 1 |
| Buckner, JC | 2 |
| Fink, KL | 1 |
| Souhami, L | 1 |
| Laperriere, NJ | 1 |
| Huse, JT | 1 |
| Mehta, MP | 1 |
| Curran, WJ | 2 |
| Taal, W | 1 |
| van der Rijt, CC | 2 |
| Dinjens, WN | 1 |
| Sillevis Smitt, PA | 3 |
| Wertenbroek, AA | 1 |
| Bromberg, JE | 1 |
| van Heuvel, I | 1 |
| Kros, JM | 3 |
| van den Bent, MJ | 5 |
| Ganesan, P | 1 |
| Rajendranath, R | 1 |
| Kannan, K | 1 |
| Radhakrishnan, V | 1 |
| Ganesan, TS | 1 |
| Udupa, K | 1 |
| Lakshmipathy, KM | 1 |
| Mahajan, V | 1 |
| Sundersingh, S | 1 |
| Rajaraman, S | 1 |
| Krishnakumar, R | 1 |
| Sagar, TG | 1 |
| Schiff, D | 2 |
| Khasraw, M | 1 |
| Lee, A | 1 |
| McCowatt, S | 1 |
| Kerestes, Z | 1 |
| Buyse, ME | 1 |
| Back, M | 1 |
| Kichenadasse, G | 1 |
| Ackland, S | 1 |
| Wheeler, H | 1 |
| Ollier, E | 1 |
| Mazzocco, P | 1 |
| Ricard, D | 1 |
| Kaloshi, G | 1 |
| Idbaih, A | 1 |
| Alentorn, A | 1 |
| Psimaras, D | 1 |
| Honnorat, J | 2 |
| Delattre, JY | 2 |
| Grenier, E | 1 |
| Ducray, F | 2 |
| Samson, A | 1 |
| Markova, J | 1 |
| Kobe, C | 1 |
| Skopalova, M | 1 |
| Klaskova, K | 1 |
| Dedeckova, K | 1 |
| Plütschow, A | 1 |
| Eich, HT | 2 |
| Dietlein, M | 1 |
| Kozak, T | 1 |
| Nicolin, G | 1 |
| Parkin, P | 1 |
| Mabbott, D | 1 |
| Hargrave, D | 1 |
| Bartels, U | 1 |
| Tabori, U | 1 |
| Rutka, J | 1 |
| Buncic, JR | 1 |
| Bouffet, E | 1 |
| Wick, W | 1 |
| Hartmann, C | 1 |
| Engel, C | 2 |
| Stoffels, M | 1 |
| Felsberg, J | 2 |
| Stockhammer, F | 1 |
| Sabel, MC | 1 |
| Koeppen, S | 1 |
| Ketter, R | 1 |
| Meyermann, R | 1 |
| Rapp, M | 1 |
| Meisner, C | 1 |
| Kortmann, RD | 1 |
| Pietsch, T | 1 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 2 |
| Reifenberger, G | 2 |
| von Deimling, A | 1 |
| Weller, M | 3 |
| Mishra, KK | 1 |
| Squire, S | 1 |
| Lamborn, K | 2 |
| Banerjee, A | 1 |
| Gupta, N | 1 |
| Wara, WM | 1 |
| Prados, MD | 4 |
| Berger, MS | 1 |
| Haas-Kogan, DA | 1 |
| Sangave, A | 1 |
| Faia, LJ | 1 |
| Yeh, S | 1 |
| Chan, CC | 1 |
| Nussenblatt, RB | 1 |
| Sen, HN | 1 |
| Halbsguth, TV | 1 |
| Nogová, L | 1 |
| Mueller, H | 1 |
| Sieniawski, M | 1 |
| Eichenauer, DA | 1 |
| Schober, T | 1 |
| Nisters-Backes, H | 1 |
| Borchmann, P | 2 |
| Diehl, V | 8 |
| Josting, A | 3 |
| Lassman, AB | 1 |
| Iwamoto, FM | 1 |
| Cloughesy, TF | 1 |
| Aldape, KD | 1 |
| Rivera, AL | 1 |
| Eichler, AF | 1 |
| Louis, DN | 1 |
| Paleologos, NA | 1 |
| Fisher, BJ | 1 |
| Ashby, LS | 1 |
| Roldán, GB | 1 |
| Wen, PY | 1 |
| Ligon, KL | 1 |
| Robins, HI | 1 |
| Rocque, BG | 1 |
| Chamberlain, MC | 2 |
| Mason, WP | 1 |
| Weaver, SA | 1 |
| Green, RM | 1 |
| Kamar, FG | 1 |
| Abrey, LE | 2 |
| DeAngelis, LM | 2 |
| Jhanwar, SC | 1 |
| Rosenblum, MK | 2 |
| Panageas, KS | 1 |
| Glas, M | 1 |
| Bähr, O | 1 |
| Rasch, K | 1 |
| Wiewrodt, D | 1 |
| Schabet, M | 1 |
| Simon, M | 1 |
| Urbach, H | 1 |
| Steinbach, JP | 1 |
| Rieger, J | 1 |
| Fimmers, R | 1 |
| Nägele, T | 1 |
| Herrlinger, U | 2 |
| Lim, SH | 1 |
| Johnson, PW | 3 |
| Fosså, A | 1 |
| Fiskvik, IH | 1 |
| Kolstad, A | 1 |
| Lauritzsen, GF | 1 |
| Aurlien, E | 1 |
| Blystad, AK | 1 |
| Hole, KH | 1 |
| Ikonomou, IM | 1 |
| Holte, H | 1 |
| Bruessow, C | 1 |
| Karrer, U | 1 |
| Gubler, J | 1 |
| Pless, M | 1 |
| Looijenga, LH | 1 |
| Langenberg, K | 1 |
| Dinjens, W | 1 |
| Graveland, W | 1 |
| Uytdewilligen, L | 1 |
| Chinot, O | 2 |
| Boogerd, W | 1 |
| Bravo Marques, J | 1 |
| Taphoorn, MJ | 2 |
| Vecht, CJ | 1 |
| De Beule, N | 1 |
| Baron, B | 1 |
| Sunyach, MP | 1 |
| Pommier, P | 1 |
| Martel Lafay, I | 1 |
| Guyotat, J | 1 |
| Ginestet, G | 1 |
| Jouanneau, E | 1 |
| Jouvet, A | 1 |
| Sindou, M | 1 |
| Bret, P | 1 |
| Carrie, C | 1 |
| Frappaz, D | 1 |
| Sieber, M | 3 |
| Bredenfeld, H | 1 |
| Reineke, T | 1 |
| Rueffer, U | 1 |
| Koch, T | 1 |
| Naumann, R | 1 |
| Boissevain, F | 3 |
| Koch, P | 3 |
| Worst, P | 2 |
| Soekler, M | 1 |
| Eich, H | 1 |
| Müller-Hermelink, HK | 2 |
| Franklin, J | 3 |
| Paulus, U | 2 |
| Wolf, J | 3 |
| Dieckmann, K | 1 |
| Pötter, R | 1 |
| Hofmann, J | 1 |
| Heinzl, H | 1 |
| Wagner, W | 1 |
| Schellong, G | 1 |
| Lancaster, DL | 1 |
| Hoddes, JA | 1 |
| Michalski, A | 1 |
| Schiller, P | 1 |
| Herrmann, R | 1 |
| De Wit, M | 1 |
| Mezger, J | 1 |
| Duhmke, E | 3 |
| Willich, N | 1 |
| Muller, RP | 2 |
| Schmidt, BF | 1 |
| Renner, H | 1 |
| Pfistner, B | 2 |
| Hasenclever, D | 2 |
| Loffler, M | 1 |
| Lai, R | 1 |
| Pandya, KJ | 1 |
| Lefkopoulou, M | 1 |
| Petrelli, NJ | 1 |
| Vaughn, DJ | 1 |
| Smith, TJ | 1 |
| Harris, JE | 1 |
| Haller, DG | 1 |
| Lebrun, C | 2 |
| Fontaine, D | 2 |
| Vandenbos, F | 2 |
| Chanalet, S | 2 |
| Bourg, V | 2 |
| Frénay, M | 2 |
| Alchaar, H | 1 |
| Bleuse, A | 1 |
| Bondiau, PY | 1 |
| Brunetto, JL | 1 |
| Chatel, M | 1 |
| Courdi, A | 1 |
| Darcourt, J | 1 |
| Fauchon, F | 2 |
| Guibert, F | 1 |
| Grellier, P | 1 |
| Lanteri-Minet, M | 1 |
| Lonjon, M | 2 |
| Michiels, JF | 1 |
| Paquis, P | 2 |
| Paquis, V | 1 |
| Ramaioli, A | 2 |
| Rasendrarijao, D | 1 |
| Sanson, M | 1 |
| Cartalat-Carel, S | 1 |
| Taillibert, S | 1 |
| Napolitano, M | 1 |
| Djafari, L | 1 |
| Cougnard, J | 1 |
| Gervais, H | 1 |
| Laigle, F | 1 |
| Carpentier, A | 1 |
| Mokhtari, K | 1 |
| Taillandier, L | 1 |
| Duffau, H | 1 |
| Hoang-Xuan, K | 1 |
| de Wit, MC | 1 |
| de Bruin, HG | 1 |
| Eijkenboom, W | 1 |
| Hudson, MM | 1 |
| Krasin, M | 1 |
| Link, MP | 1 |
| Donaldson, SS | 1 |
| Billups, C | 1 |
| Merchant, TE | 1 |
| Kun, L | 1 |
| Billet, AL | 1 |
| Kaste, S | 1 |
| Tarbell, NJ | 1 |
| Howard, S | 1 |
| Friedmann, AM | 1 |
| Hurwitz, CA | 1 |
| Young, JA | 1 |
| Marcus, KC | 1 |
| Rai, S | 1 |
| Cowan, T | 1 |
| Weinstein, HJ | 1 |
| Macdonald, DR | 1 |
| Kiebert, G | 1 |
| Prados, M | 2 |
| Yung, A | 1 |
| Olson, J | 1 |
| Bonadonna, G | 1 |
| Bonfante, V | 1 |
| Fisher, B | 1 |
| Seiferheld, W | 1 |
| Schultz, C | 2 |
| DeAngelis, L | 1 |
| Nelson, D | 1 |
| Schold, SC | 1 |
| Curran, W | 1 |
| Mehta, M | 1 |
| Radford, JA | 1 |
| Cullen, MH | 1 |
| Sydes, MR | 1 |
| Walewski, J | 1 |
| Jack, AS | 1 |
| MacLennan, KA | 1 |
| Stenning, SP | 1 |
| Clawson, S | 1 |
| Smith, P | 1 |
| Ryder, D | 1 |
| Hancock, BW | 1 |
| Schmidt, F | 1 |
| Fischer, J | 1 |
| Dietz, K | 1 |
| Dichgans, J | 1 |
| Piccirilli, M | 1 |
| Landi, A | 1 |
| Salvati, M | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Batchelor, TT | 1 |
| Lesser, G | 1 |
| Mikkelsen, T | 2 |
| Alavi, JB | 1 |
| Phuphanich, S | 1 |
| Hammour, T | 1 |
| Fisher, JD | 1 |
| Supko, JG | 1 |
| Walker, C | 1 |
| Haylock, B | 1 |
| Husband, D | 1 |
| Joyce, KA | 1 |
| Fildes, D | 1 |
| Jenkinson, MD | 1 |
| Smith, T | 1 |
| Broome, J | 1 |
| Kopitzki, K | 1 |
| du Plessis, DG | 1 |
| Prosser, J | 1 |
| Vinjamuri, S | 1 |
| Warnke, PC | 1 |
| Klimm, B | 1 |
| Haverkamp, H | 1 |
| Lohri, A | 1 |
| Trenn, G | 1 |
| Müller-Hermelink, K | 1 |
| Simon, Z | 1 |
| Keresztes, K | 1 |
| Miltényi, Z | 1 |
| Ress, Z | 1 |
| Váróczy, L | 1 |
| Vadász, G | 1 |
| Gergely, L | 1 |
| Illés, A | 1 |
| Yang, SH | 1 |
| Hong, YK | 1 |
| Yoon, SC | 1 |
| Kim, BS | 1 |
| Lee, YS | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Kim, MC | 1 |
| Park, CK | 1 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Galanis, E | 1 |
| Lévy, R | 1 |
| Colonna, P | 1 |
| Tourani, JM | 1 |
| Gastaut, JA | 1 |
| Raphaël, M | 1 |
| Taillan, B | 1 |
| Andrieu, JM | 1 |
| Levin, VA | 6 |
| Maor, MH | 2 |
| Thall, PF | 1 |
| Yung, WK | 6 |
| Bruner, J | 2 |
| Sawaya, R | 1 |
| Kyritsis, AP | 5 |
| Leeds, N | 1 |
| Woo, S | 1 |
| Rodriguez, L | 1 |
| Malpas, JS | 1 |
| Ganjoo, RK | 1 |
| Mahmoud, MM | 1 |
| Williams, AH | 1 |
| Carter, M | 1 |
| Gregory, W | 1 |
| Lim, JM | 1 |
| Love, SB | 1 |
| Clark, PI | 1 |
| Jeremic, B | 1 |
| Grujicic, D | 1 |
| Antunovic, V | 1 |
| Djuric, L | 1 |
| Stojanovic, M | 1 |
| Shibamoto, Y | 1 |
| Haim, N | 1 |
| Leviov, M | 1 |
| Ben-Arieh, Y | 1 |
| Epelbaum, R | 1 |
| Freidin, N | 1 |
| Reshef, R | 1 |
| Ben-Shahar, M | 1 |
| Jaeckle, KA | 4 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Edwards, MS | 1 |
| Rabbitt, J | 1 |
| Davis, RL | 1 |
| Kaba, SE | 1 |
| Hess, K | 2 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Davidge-Pitts, M | 1 |
| Dansey, R | 1 |
| Bezwoda, WR | 1 |
| Wirth, A | 1 |
| Corry, J | 1 |
| Laidlaw, C | 1 |
| Matthews, J | 1 |
| Liew, KH | 1 |
| Mac Manus, MP | 1 |
| Hoppe, RT | 1 |
| Tesch, H | 2 |
| Pfreundschuh, M | 1 |
| Lathan, B | 1 |
| Rüffer, JU | 1 |
| Sextro, M | 1 |
| Hermann, R | 1 |
| Holmer, L | 1 |
| Stappert-Jahn, U | 1 |
| Winnerlein-Trump, E | 1 |
| Wulf, G | 1 |
| Krause, S | 1 |
| Glunz, A | 1 |
| von Kalle, K | 1 |
| Bischoff, H | 1 |
| Haedicke, C | 1 |
| Georgii, A | 1 |
| Loeffler, M | 2 |
| Brandes, AA | 1 |
| Ermani, M | 1 |
| Turazzi, S | 1 |
| Scelzi, E | 1 |
| Berti, F | 1 |
| Amistà, P | 1 |
| Rotilio, A | 1 |
| Licata, C | 1 |
| Fiorentino, MV | 1 |
| Saletti, P | 1 |
| Zucca, E | 1 |
| Gueneau, M | 1 |
| Peccatori, F | 1 |
| Cavalli, F | 2 |
| Martinelli, G | 1 |
| Groves, MD | 1 |
| Meyers, C | 1 |
| Sawaya, RE | 1 |
| Bruner, JM | 1 |
| Peterson, P | 1 |
| Scott, C | 1 |
| Sandler, H | 1 |
| Phillips, T | 1 |
| Urtasun, R | 1 |
| Davis, R | 1 |
| Gutin, P | 1 |
| Cascino, TL | 1 |
| Greenberg, HS | 1 |
| Meddeb, B | 1 |
| Ben Lakhal, R | 1 |
| Bel Hadj Ali, Z | 1 |
| Ben Abid, H | 1 |
| Hafsia, R | 1 |
| Hafsia, A | 1 |
| Osoba, D | 1 |
| Brada, M | 1 |
| Fisher, RI | 1 |
| Dana, BW | 1 |
| LeBlanc, M | 1 |
| Kjeldsberg, C | 1 |
| Forman, JD | 1 |
| Unger, JM | 1 |
| Balcerzak, SP | 1 |
| Gaynor, ER | 1 |
| Roy, V | 1 |
| Miller, T | 1 |
| Boiardi, A | 2 |
| Eoli, M | 1 |
| Pozzi, A | 1 |
| Salmaggi, A | 1 |
| Broggi, G | 1 |
| Silvani, A | 1 |
| Schmitz, S | 1 |
| Kappelle, AC | 1 |
| Postma, TJ | 1 |
| Groeneveld, GJ | 1 |
| van Groeningen, CJ | 1 |
| Zonnenberg, BA | 1 |
| Sneeuw, KC | 1 |
| Heimans, JJ | 1 |
| Cairncross, G | 1 |
| Swinnen, L | 1 |
| Bayer, R | 1 |
| Rosenfeld, S | 1 |
| Salzman, D | 1 |
| Paleologos, N | 1 |
| Kaminer, L | 1 |
| Forsyth, P | 1 |
| Stewart, D | 1 |
| Peterson, K | 1 |
| Hu, W | 1 |
| Macdonald, D | 1 |
| Ramsay, D | 1 |
| Smith, A | 1 |
| Colin, P | 1 |
| Berger, F | 1 |
| de Kerviler, E | 1 |
| Diviné, M | 1 |
| Bouaffia, F | 1 |
| Kerneis, Y | 1 |
| Blanc, M | 1 |
| Lepage, E | 1 |
| Fermé, C | 1 |
| Hess, KR | 1 |
| Wong, ET | 1 |
| Croteau, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Interim PET-CT Scan-guided Response Adapted Therapy in Hodgkin's Lymphoma[NCT01304849] | 50 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [NCT00284271] | Phase 2 | 65 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)[NCT03576378] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2018-08-08 | Active, not recruiting | ||
| Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304] | Phase 2 | 29 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease[NCT00003421] | Phase 3 | 800 participants (Anticipated) | Interventional | 1998-06-30 | Completed | ||
| Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy[NCT00188149] | Phase 4 | 300 participants | Interventional | 2000-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for procarbazine and Disease Exacerbation
| Article | Year |
|---|---|
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, | 2020 |
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Daca | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Chemotherapy for diffuse low-grade gliomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother | 2011 |
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries | 2003 |
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cranial Irradia | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 1995 |
Overview of treatment of localized low-grade lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; California; Chemotherap | 1997 |
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1998 |
Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Clinical Trials, Phase III | 2000 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
37 trials available for procarbazine and Disease Exacerbation
| Article | Year |
|---|---|
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chi-Square Distr | 2014 |
Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamid | 2015 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine | 2016 |
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dise | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Di | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2011 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphami | 2003 |
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi | 2003 |
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymph
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2003 |
Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Disease Progression; D | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2004 |
Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cognition; Combined Modality | 2005 |
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Co | 2005 |
PCV chemotherapy for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; D | 2006 |
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Antineoplastic Agents; Cohort Studies; Disease P | 2006 |
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2007 |
Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Disease | 2007 |
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 1995 |
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 1995 |
Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 1995 |
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1997 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1998 |
Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain; Brain N | 1999 |
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain | 1999 |
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che | 1999 |
[Results of a prospective protocol for the treatment of adult Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Disease Progression; D | 1999 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2000 |
Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Platelets; | 2000 |
Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Disease Progression; Doxorubicin; | 2001 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
31 other studies available for procarbazine and Disease Exacerbation
| Article | Year |
|---|---|
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cost-Bene | 2017 |
Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Diseases; Brentuximab Vedotin; Cycl | 2019 |
Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Drug Therapy, Combination; Femal | 2015 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dise | 2017 |
Natural history and outcome of optic pathway gliomas in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Damage, Chronic; Carboplatin; Chil | 2009 |
A case of rapid progression and vision loss in a patient with primary intraocular lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blindness; Disease Progression; Eye Neoplasms; | 2010 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr | 2011 |
Chemotherapy: Advanced Hodgkin lymphoma--balancing toxicity and cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Consolidation | 2011 |
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant | 2012 |
Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bleomycin; Combined Modality Therapy; Cy | 2011 |
Homonymous hemianopsia in a patient with Hodgkin's lymphoma in remission after BEACOPP chemotherapy.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; | 2012 |
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes | 2003 |
Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pres | 2003 |
[Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt | 2004 |
Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Dacarbazine; Disea | 2005 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2006 |
Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, | 2006 |
[Our experiences in treating patients with Hodgkin disease in the last decade].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Ad | 2007 |
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2007 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
Myeloma during a decade: clinical experience in a single centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1995 |
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch | 1994 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cycl | 1997 |
Salvage radiotherapy for Hodgkin's disease following chemotherapy failure.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Dacarbazine; Di | 1997 |
ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Disease Progre | 1999 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Glioblasto | 2001 |
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 2000 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Female; Gliobl | 2001 |